VSTM, US92337C2035

Verastem Oncology prices USD 250 million offering for Verastem Oncology stock

Published on 10/22/2026 at 13:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Verastem priced USD 250.00 million offering on October 14, 2026. Verastem Oncology stock traded at EUR 8.16 on October 22, 2026.

Clinical data and funding milestones

Verastem priced a USD 250.00 million offering on October 14, 2026.
VS-7375 produced a 50.00 percent confirmed response rate in second-line pancreatic cancer on October 14, 2026.
Verastem Oncology stock was trading at EUR 8.16 at 1:43 p.m. CEST at Lang & Schwarz on October 22, 2026.

VSTM, US92337C2035, Illustration mit AI erstellt.

Verastem Oncology (ISIN US92337C2035) was trading at EUR 8.16 at Lang & Schwarz on October 22, 2026 at 1:43 p.m. CEST. The company priced a USD 250.00 million stock offering on October 14, 2026, while new clinical data added a second catalyst for its oncology pipeline.

According to Verastem Oncology, the financing comprised 30,937,500 common shares priced at USD 8.00 each and pre-funded warrants for up to 312,503 additional shares. The company said it expected gross proceeds of USD 250.00 million before underwriting discounts and other expenses.

Why does the financing matter?

The proceeds are earmarked for continued clinical development, including the VS-7375 program, and for working capital. The financing strengthens Verastem's funding position for development work, but the new securities also expand the share base and can dilute existing ownership.

Three dated milestones

On October 2, 2026, Verastem presented RAMP 201 findings showing an 18.00 percent confirmed objective response rate in patients with triple-wild-type recurrent low-grade serous ovarian cancer, according to StockTitan. On October 14, 2026, Verastem Oncology reported a 50.00 percent confirmed response rate in second-line pancreatic cancer at the 900 milligram daily dose, based on 4 of 8 patients.

Later on October 14, 2026, the company announced the USD 250.00 million offering. The sequence links the funding directly to a pipeline that is producing measurable response data, although the clinical results remain tied to ongoing trials.

What does the pipeline data show?

The VS-7375 update also reported a 41.00 percent confirmed response rate in the second-line-or-later setting, covering 9 of 22 patients and including two complete responses. For investors, the key distinction is between early response data and the later evidence required for regulatory and commercial decisions.

Next reporting date is November 3

Zacks lists November 3, 2026 as Verastem's next expected earnings date for the period ending September 2026. The upcoming report should give investors a fresh view of commercial progress after the second-quarter revenue of USD 40.08 million and diluted loss of USD 0.35 per share reported for the quarter ended June 30, 2026.

Stock quote in euros

Verastem Oncology is listed on Nasdaq under ticker VSTM and develops medicines for cancers driven by RAS/MAPK pathway signaling. Its current euro indication was EUR 8.16 at Lang & Schwarz on October 22, 2026 at 1:43 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Verastem Oncology stock.